ClinicalTrials.gg
RecruitingNCT06718842Updated Dec 5, 2024

Walking Program in Fatty Liver Children With Phenylketonuria

An interventional study of walking free online supervised program in Phenylketonurias and Non Alcoholic Fatty Liver, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 9 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
9 Years to 12 Years
Sex
All
01

Study summary

phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood. PKU is usually associated with many metabolic complication including non-alcoholic fatty liver

Read the detailed description

this study will include PKU children sufferers 9n=40) with non-alcoholic fatty liver to be randomly assigned to group I (n=20) that will perform walking program (online supervised free walking that will be applied daily for eight weeks) or group II (N=20) that will act as waitlisted children

02

Conditions studied

  • Phenylketonurias
  • Non Alcoholic Fatty Liver
03

In context

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

This study's planned enrollment of 40 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.

Browse Phenylketonurias studies →

Lead sponsor

Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PKU children
  • obese children
  • fatty liver children (non-alcoholic fatty liver)

Exclusion criteria

Exclusion Criteria:

  • cardiac children
  • diabetic children
  • neurogenic disorders
  • respiratory and renal problems
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group I

    this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)

    Behavioral: walking free online supervised program

  • No intervention
    Group II

    this Group II will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will act a waitlisted children

Interventions

  • Behavioralwalking free online supervised program

    this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)

06

What researchers measure

Primary outcomes

  1. alanine transamianse

    it is a serum liver enzyme

    Time frame: it will be assessed after eight weeks

Secondary outcomes

  1. aspartate tranaminase

    it is a serum liver enzyme

    Time frame: it will be assessed after eight weeks

  2. Gamma-glutamyl Transferase

    it is a serum liver enzyme

    Time frame: it will be assessed after eight weeks

  3. alkaline phosphatase

    it is a serum liver enzyme

    Time frame: it will be assessed after eight weeks

  4. triglycerides

    it will be measured in the serum

    Time frame: it will be assessed after eight weeks

  5. body mass index

    it will be measured after emptying bladder

    Time frame: it will be assessed after eight weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jan 2025, 4 months after the start.

Of 33 interventional studies with no phase under Phenylketonurias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 5, 2024
StartActual
Sep 15, 2024
Primary completionEst.
Jan 30, 2025
CompletionEst.
Jan 30, 2025
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06718842
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (Department of Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University) — Principal investigator
First posted
Dec 5, 2024
Start date
Sep 15, 2024
Primary completion
Jan 30, 2025 (estimated)
Completion
Jan 30, 2025 (estimated)
Last update
Dec 5, 2024

Study contacts

Ali Isamil, Lecturer
Contact
ali.mohamed@pt.cu.edu.eg
0201005154209
shimaaa bondok, PHD
Contact
dr.shymaa_bondok@yahoo.com
02 101 565 5118
Ali Ismail, lecturer
study chair · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion